nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

31.07.2019 | Editorial

Molecular imaging of impulse control disorders in Parkinson’s disease

verfasst von: Joonas Majuri, Juho Joutsa

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Excerpt

Impulse control disorders (ICDs) affect approximately one seventh of patients with Parkinson’s disease (PD) [1]. Common ICDs include gambling disorder, hypersexuality, compulsive shopping, and binge eating. These disorders have been strongly linked to dopamine replacement therapy and, especially gambling disorder, share many clinical features with substance addictions [1, 2]. However, not all patients develop ICDs with dopamine replacement therapy, but the reasons for this and the neurobiological mechanisms underlying ICDs are still relatively poorly understood. …

Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95. https://doi.org/10.1001/archneurol.2010.65.CrossRefPubMed

Yau YH, Potenza MN. Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. 2015;23:134–46. https://doi.org/10.1097/HRP.0000000000000051.CrossRefPubMedPubMedCentral

Navalpotro-Gomez I, Dacosta-Aguayo R, Molinet-Dronda F, Martin-Bastida A, Botas-Peñin A, Jimenez-Urbieta H, et al. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04396-3.

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73. https://doi.org/10.1016/S2215-0366(16)00104-8.CrossRefPubMedPubMedCentral

Cilia R, Ko JH, Cho SS, van Eimeren T, Marotta G, Pellecchia G, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis. 2010;39:98–104. https://doi.org/10.1016/j.nbd.2010.03.013.CrossRefPubMed

Lee JY, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson’s disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85:23–30. https://doi.org/10.1136/jnnp-2013-305549.CrossRefPubMed

Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, et al. Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry. 2014;85:148–52. https://doi.org/10.1136/jnnp-2013-305395.CrossRefPubMed

Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, Voorn P, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease. Mov Disord. 2014;29:904–11. https://doi.org/10.1002/mds.25886.CrossRefPubMed

Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: a lateralized monoaminergic frontostriatal disconnection syndrome? Parkinsonism Relat Disord. 2016;30:62–6. https://doi.org/10.1016/j.parkreldis.2016.05.028.CrossRefPubMed

10.

Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. J Neurol Neurosurg Psychiatry. 2016;87:864–70. https://doi.org/10.1136/jnnp-2015-311827.CrossRefPubMed

11.

Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132:1376–85. https://doi.org/10.1093/brain/awp054.CrossRefPubMedPubMedCentral

12.

O’Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, et al. Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain. 2011;134:969–78. https://doi.org/10.1093/brain/awr003.CrossRefPubMed

13.

Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis. 2012;48:519–25. https://doi.org/10.1016/j.nbd.2012.06.021.CrossRefPubMedPubMedCentral

14.

Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, et al. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson’s disease with impulse control disorders. Mov Disord. 2015;30:160–6. https://doi.org/10.1002/mds.26135. CrossRefPubMed

15.

Wu K, Politis M, O’Sullivan SS, Lawrence AD, Warsi S, Bose S, et al. Single versus multiple impulse control disorders in Parkinson’s disease: an ¹¹C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. J Neurol. 2015;262:1504–14. https://doi.org/10.1007/s00415-015-7722-7.CrossRefPubMed

16.

Stark AJ, Smith CT, Lin YC, Petersen KJ, Trujillo P, van Wouwe NC, et al. Nigrostriatal and mesolimbic D2/3 receptor expression in Parkinson’s disease patients with compulsive reward-driven behaviors. J Neurosci. 2018;38:3230–9. https://doi.org/10.1523/JNEUROSCI.3082-17.2018.CrossRefPubMedPubMedCentral

17.

Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88:1461–7. https://doi.org/10.1212/WNL.0000000000003810.CrossRefPubMed

18.

Honkanen EA, Saari L, Orte K, Gardberg M, Noponen T, Joutsa J, et al. No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson’s disease. Mov Disord. 2019. https://doi.org/10.1002/mds.27777.

19.

Joutsa J, Martikainen K, Niemelä S, Johansson J, Forsback S, Rinne JO, et al. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord. 2012;27:778–82. https://doi.org/10.1002/mds.24941.CrossRefPubMed

20.

Joutsa J, Johansson J, Niemelä S, Ollikainen A, Hirvonen MM, Piepponen P, et al. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage. 2012;60:1992–9. https://doi.org/10.1016/j.neuroimage.2012.02.006.CrossRefPubMed

21.

Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, et al. In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO. Mol Psychiatry. 2014;19:1305–13. https://doi.org/10.1038/mp.2013.163.CrossRefPubMed

22.

Majuri J, Joutsa J, Johansson J, Voon V, Alakurtti K, Parkkola R, et al. Dopamine and opioid neurotransmission in behavioral addictions: a comparative PET study in pathological gambling and binge eating. Neuropsychopharmacology. 2017;42:1169–77. https://doi.org/10.1038/npp.2016.265.CrossRefPubMed

23.

Pettorruso M, Martinotti G, Cocciolillo F, De Risio L, Cinquino A, Di Nicola M, et al. Striatal presynaptic dopaminergic dysfunction in gambling disorder: a ¹²³I‐FP‐CIT SPECT study. Addict Biol. 2018. https://doi.org/10.1111/adb.12677.

24.

Hammes J, Theis H, Giehl K, Hoenig MC, Greuel A, Tittgemeyer M, et al. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 2019;142:733–43. https://doi.org/10.1093/brain/awz007.CrossRefPubMed

25.

Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol. 2011;24:324–30. https://doi.org/10.1097/WCO.0b013e3283489687.CrossRefPubMedPubMedCentral

26.

Eklund A, Nichols TE, Knutsson H. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A. 2016;113:7900–5. https://doi.org/10.1073/pnas.1602413113.CrossRefPubMedPubMedCentral

27.

Verger A, Klesse E, Chawki MB, Witjas T, Azulay JP, Eusebio A, et al. Brain PET substrate of impulse control disorders in Parkinson’s disease: a metabolic connectivity study. Hum Brain Mapp. 2018;39:3178–86. https://doi.org/10.1002/hbm.24068.CrossRefPubMed

Titel: Molecular imaging of impulse control disorders in Parkinson’s disease
verfasst von: Joonas Majuri
Juho Joutsa
Publikationsdatum: 31.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04459-5

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Molecular imaging of impulse control disorders in Parkinson’s disease

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2019

Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

No differences in rest myocardial blood flow in stunned and hibernating myocardium: insights into the pathophysiology of ischemic cardiomyopathy

Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors

Radiation-induced myocardial damage indicated by focal defect on 123I-MIBG SPECT

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics